CA1320114C - Methode et trousse pour epreuve de neutralisation/immuno-inhibition - Google Patents

Methode et trousse pour epreuve de neutralisation/immuno-inhibition

Info

Publication number: CA1320114C
Authority: CA; Canada
Prior art keywords: isoenzyme; sample; serum; diagnostically relevant; immunoinhibition
Prior art date: 1987-05-12
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

CA000566474A

Other languages

English (en)

Inventor

Frank J. Lucas

Show-Jiuan Ho, (Susan)

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Coulter Electronics Inc

Original Assignee

Coulter Electronics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-05-12

Filing date

1988-05-11

Publication date

1993-07-13

1988-05-11 Application filed by Coulter Electronics Inc filed Critical Coulter Electronics Inc

1993-07-13 Application granted granted Critical

1993-07-13 Publication of CA1320114C publication Critical patent/CA1320114C/fr

2010-07-13 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

238000000034 method Methods 0.000 title claims abstract description 69
238000003556 assay Methods 0.000 title claims abstract description 28
238000006386 neutralization reaction Methods 0.000 title claims abstract description 28
238000012360 testing method Methods 0.000 title claims abstract description 12
108010044467 Isoenzymes Proteins 0.000 claims abstract description 90
230000002255 enzymatic effect Effects 0.000 claims abstract description 36
230000000694 effects Effects 0.000 claims abstract description 32
102000004190 Enzymes Human genes 0.000 claims abstract description 30
108090000790 Enzymes Proteins 0.000 claims abstract description 30
239000013060 biological fluid Substances 0.000 claims abstract description 18
239000000758 substrate Substances 0.000 claims description 25
102000004420 Creatine Kinase Human genes 0.000 claims description 22
108010042126 Creatine kinase Proteins 0.000 claims description 22
238000012937 correction Methods 0.000 claims description 15
238000005259 measurement Methods 0.000 claims description 15
238000012544 monitoring process Methods 0.000 claims description 10
238000012545 processing Methods 0.000 claims description 10
230000002159 abnormal effect Effects 0.000 claims description 6
238000006243 chemical reaction Methods 0.000 claims description 6
230000001376 precipitating effect Effects 0.000 claims description 6
241001465754 Metazoa Species 0.000 claims description 5
230000015572 biosynthetic process Effects 0.000 claims description 5
230000007170 pathology Effects 0.000 claims description 5
238000004519 manufacturing process Methods 0.000 claims description 4
241000288906 Primates Species 0.000 claims description 3
239000000470 constituent Substances 0.000 claims description 3
230000004962 physiological condition Effects 0.000 claims description 3
238000001514 detection method Methods 0.000 claims description 2
238000013459 approach Methods 0.000 claims 2
206010000891 acute myocardial infarction Diseases 0.000 abstract description 13
230000009429 distress Effects 0.000 abstract description 7
230000007717 exclusion Effects 0.000 abstract description 4
230000005764 inhibitory process Effects 0.000 abstract description 2
239000000523 sample Substances 0.000 description 43
229940088598 enzyme Drugs 0.000 description 23
238000012552 review Methods 0.000 description 10
210000002966 serum Anatomy 0.000 description 8
239000003153 chemical reaction reagent Substances 0.000 description 7
238000004458 analytical method Methods 0.000 description 6
230000003993 interaction Effects 0.000 description 6
239000013610 patient sample Substances 0.000 description 5
238000000926 separation method Methods 0.000 description 5
238000000375 direct analysis in real time Methods 0.000 description 4
238000012063 dual-affinity re-targeting Methods 0.000 description 4
239000002244 precipitate Substances 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
101710088194 Dehydrogenase Proteins 0.000 description 3
102000015439 Phospholipases Human genes 0.000 description 3
108010064785 Phospholipases Proteins 0.000 description 3
238000003149 assay kit Methods 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
238000011161 development Methods 0.000 description 3
230000018109 developmental process Effects 0.000 description 3
230000000984 immunochemical effect Effects 0.000 description 3
239000000203 mixture Substances 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
230000008569 process Effects 0.000 description 3
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
241000283707 Capra Species 0.000 description 2
230000010665 Enzyme Interactions Effects 0.000 description 2
108091000080 Phosphotransferase Proteins 0.000 description 2
239000004365 Protease Substances 0.000 description 2
239000002253 acid Substances 0.000 description 2
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 2
229950006790 adenosine phosphate Drugs 0.000 description 2
230000009833 antibody interaction Effects 0.000 description 2
239000000427 antigen Substances 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
230000000295 complement effect Effects 0.000 description 2
CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
230000009260 cross reactivity Effects 0.000 description 2
230000007423 decrease Effects 0.000 description 2
238000003745 diagnosis Methods 0.000 description 2
238000002405 diagnostic procedure Methods 0.000 description 2
230000004069 differentiation Effects 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
208000014674 injury Diseases 0.000 description 2
150000002500 ions Chemical class 0.000 description 2
230000000737 periodic effect Effects 0.000 description 2
102000020233 phosphotransferase Human genes 0.000 description 2
230000035790 physiological processes and functions Effects 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
238000010998 test method Methods 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
102100032534 Adenosine kinase Human genes 0.000 description 1
108020000543 Adenylate kinase Proteins 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108050004944 Alpha-glucan phosphorylases Proteins 0.000 description 1
239000004382 Amylase Substances 0.000 description 1
102000013142 Amylases Human genes 0.000 description 1
108010065511 Amylases Proteins 0.000 description 1
208000030853 Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome Diseases 0.000 description 1
102100026189 Beta-galactosidase Human genes 0.000 description 1
108010004032 Bromelains Proteins 0.000 description 1
239000002126 C01EB10 - Adenosine Substances 0.000 description 1
102000005367 Carboxypeptidases Human genes 0.000 description 1
108010006303 Carboxypeptidases Proteins 0.000 description 1
102100035882 Catalase Human genes 0.000 description 1
108010053835 Catalase Proteins 0.000 description 1
UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
102000016911 Deoxyribonucleases Human genes 0.000 description 1
108010053770 Deoxyribonucleases Proteins 0.000 description 1
101100353161 Drosophila melanogaster prel gene Proteins 0.000 description 1
102000013382 Gelatinases Human genes 0.000 description 1
108010026132 Gelatinases Proteins 0.000 description 1
102000005731 Glucose-6-phosphate isomerase Human genes 0.000 description 1
108010070600 Glucose-6-phosphate isomerase Proteins 0.000 description 1
206010018910 Haemolysis Diseases 0.000 description 1
102000005548 Hexokinase Human genes 0.000 description 1
108700040460 Hexokinases Proteins 0.000 description 1
102000015860 Hyaluronidase-3 Human genes 0.000 description 1
108050004076 Hyaluronidase-3 Proteins 0.000 description 1
102100034343 Integrase Human genes 0.000 description 1
102000004882 Lipase Human genes 0.000 description 1
108090001060 Lipase Proteins 0.000 description 1
239000004367 Lipase Substances 0.000 description 1
102100024295 Maltase-glucoamylase Human genes 0.000 description 1
102000016943 Muramidase Human genes 0.000 description 1
108010014251 Muramidase Proteins 0.000 description 1
108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
102000005348 Neuraminidase Human genes 0.000 description 1
108010006232 Neuraminidase Proteins 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
108090000526 Papain Proteins 0.000 description 1
108010087702 Penicillinase Proteins 0.000 description 1
108010053763 Pyruvate Carboxylase Proteins 0.000 description 1
102100039895 Pyruvate carboxylase, mitochondrial Human genes 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
108090000794 Streptopain Proteins 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
102100040653 Tryptophan 2,3-dioxygenase Human genes 0.000 description 1
101710136122 Tryptophan 2,3-dioxygenase Proteins 0.000 description 1
108010075344 Tryptophan synthase Proteins 0.000 description 1
102000014384 Type C Phospholipases Human genes 0.000 description 1
108010079194 Type C Phospholipases Proteins 0.000 description 1
102100039094 Tyrosinase Human genes 0.000 description 1
108060008724 Tyrosinase Proteins 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
102100033220 Xanthine oxidase Human genes 0.000 description 1
108010093894 Xanthine oxidase Proteins 0.000 description 1
229960005305 adenosine Drugs 0.000 description 1
230000004520 agglutination Effects 0.000 description 1
108010028144 alpha-Glucosidases Proteins 0.000 description 1
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
235000019418 amylase Nutrition 0.000 description 1
239000012491 analyte Substances 0.000 description 1
108010005774 beta-Galactosidase Proteins 0.000 description 1
QTPILKSJIOLICA-UHFFFAOYSA-N bis[hydroxy(phosphonooxy)phosphoryl] hydrogen phosphate Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(O)=O QTPILKSJIOLICA-UHFFFAOYSA-N 0.000 description 1
230000036765 blood level Effects 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
235000019835 bromelain Nutrition 0.000 description 1
244000309464 bull Species 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
230000008859 change Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
230000001010 compromised effect Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
229960003624 creatine Drugs 0.000 description 1
239000006046 creatine Substances 0.000 description 1
230000006378 damage Effects 0.000 description 1
238000013523 data management Methods 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
239000000539 dimer Substances 0.000 description 1
238000005187 foaming Methods 0.000 description 1
108010032776 glycerol-1-phosphatase Proteins 0.000 description 1
235000015220 hamburgers Nutrition 0.000 description 1
210000002216 heart Anatomy 0.000 description 1
230000008588 hemolysis Effects 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
238000001114 immunoprecipitation Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
235000019421 lipase Nutrition 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
229960000274 lysozyme Drugs 0.000 description 1
239000004325 lysozyme Substances 0.000 description 1
235000010335 lysozyme Nutrition 0.000 description 1
239000000463 material Substances 0.000 description 1
230000002438 mitochondrial effect Effects 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
229940055729 papain Drugs 0.000 description 1
235000019834 papain Nutrition 0.000 description 1
239000002245 particle Substances 0.000 description 1
229950009506 penicillinase Drugs 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
238000011002 quantification Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
238000005070 sampling Methods 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
210000002027 skeletal muscle Anatomy 0.000 description 1
210000002460 smooth muscle Anatomy 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000008733 trauma Effects 0.000 description 1
239000012588 trypsin Substances 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Chemical & Material Sciences (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Cell Biology (AREA)
Food Science & Technology (AREA)
Medicinal Chemistry (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

CA000566474A 1987-05-12 1988-05-11 Methode et trousse pour epreuve de neutralisation/immuno-inhibition Expired - Fee Related CA1320114C (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US4871287A	1987-05-12	1987-05-12
US07/048,712		1987-05-12

Publications (1)

Publication Number	Publication Date
CA1320114C true CA1320114C (fr)	1993-07-13

Family

ID=21956040

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000566474A Expired - Fee Related CA1320114C (fr)	1987-05-12	1988-05-11	Methode et trousse pour epreuve de neutralisation/immuno-inhibition

Country Status (5)

Country	Link
EP (1)	EP0382725A4 (fr)
JP (1)	JPH01503565A (fr)
AU (1)	AU1800088A (fr)
CA (1)	CA1320114C (fr)
WO (1)	WO1988008984A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1991019983A1 (fr) *	1990-06-21	1991-12-26	Axis Research As	Analyse de variantes d'analytes

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2548963C3 (de) *	1975-11-03	1982-03-11	Merck Patent Gmbh, 6100 Darmstadt	Verfahren und Mittel zur Bestimmung der Aktivität von Creatinkinase-MB

1988
- 1988-05-11 AU AU18000/88A patent/AU1800088A/en not_active Abandoned
- 1988-05-11 WO PCT/US1988/001553 patent/WO1988008984A1/fr not_active Ceased
- 1988-05-11 CA CA000566474A patent/CA1320114C/fr not_active Expired - Fee Related
- 1988-05-11 EP EP19880904874 patent/EP0382725A4/en not_active Withdrawn
- 1988-05-11 JP JP63504588A patent/JPH01503565A/ja active Pending

Also Published As

Publication number	Publication date
AU1800088A (en)	1988-12-06
JPH01503565A (ja)	1989-11-30
EP0382725A1 (fr)	1990-08-22
WO1988008984A1 (fr)	1988-11-17
EP0382725A4 (en)	1990-12-27

Legal Events

Date	Code	Title	Description
1997-07-14	MKLA	Lapsed

Publication	Publication Date	Title
US4067775A (en)	1978-01-10	Process and composition for determining the activity of creatinekinase-MB
JP3686423B2 (ja)	2005-08-24	慢性疲労症候群の検出方法
US4515890A (en)	1985-05-07	Immunoassay of terminal deoxynucleotidyl transferase
Mulivor et al.	1979	Origin of the alkaline phosphatases in amniotic fluid
US7462495B2 (en)	2008-12-09	Methods and compositions for use in diagnosing and characterizing chronic immune disease
US4387160A (en)	1983-06-07	Immunochemical assay for creatine kinase-MB isoenzyme
US4543325A (en)	1985-09-24	Process and reagent for the determination of creatinine
US4237044A (en)	1980-12-02	Antibodies against creatinekinase-M8 and process for the production thereof
CA1320114C (fr)	1993-07-13	Methode et trousse pour epreuve de neutralisation/immuno-inhibition
US4673633A (en)	1987-06-16	Method of determining cystic fibrosis ciliostatic factor
CA2513317A1 (fr)	2006-01-06	Composition contenant de l'aldolase pour le diagnostic d'une maladie vasculaire au niveau de la retine et methode diagnostique connexe
US4330620A (en)	1982-05-18	Method and reagent for the determination of creatine kinase MB
JP3014752B2 (ja)	2000-02-28	細胞の活性化を測定するための酵素アッセイおよびアッセイキット
JP4043053B2 (ja)	2008-02-06	生物学上の流体中のプロカルボキシペプチダーゼａおよびカルボキシペプチダーゼａレベルの検出方法
WO1993004374A1 (fr)	1993-03-04	Determination des isoenzymes et des isoformes de la creatine-kinase
Wong et al.	1987	Evaluation of a kinetic assay for angiotensin converting enzyme
Lukomskaya et al.	1996	Use of β-maltosides (p-nitrophenyl-β-d-maltoside, 2-chloro-4-nitrophenyl-β-d-maltoside and 4-methylumbelliferyl-β-d-maltoside) as substrates for the assay of neutral α-glucosidase from human kidney and urine
CA1062609A (fr)	1979-09-18	Procede et compose pour mesurer l'activite de la creatinekinase-mb
US20060269963A1 (en)	2006-11-30	Composition for the diagnosis of retinal vascular disease comprising aldolase and method for diagnosis using it
Agostoni et al.	0	Abels, J., see Van Kapel, J.(131) 211 Abraham, RT. see Keith, RA (131) 257 A, Inm hd..... I n,.., 7 i-ua,“A_ Pll”“CJ”, L. Altered expression of collagen phenotype in osteoarthrosis (133) 25
EP0185432A2 (fr)	1986-06-25	Méthode immunoenzymatique pour la détermination des analytes et composition appropriée pour ce but
BIRCHER et al.	1969	ALESSIO, L. see FIORELLI, G...... 177 ANDERSON, NG
JPH11103892A (ja)	1999-04-20	アイソザイム活性測定法
JPH0578315B2 (fr)	1993-10-28